Liver Cancer Drug Market (2026 - 2033)

Liver Cancer Drug Market Summary

The global liver cancer drug market size was valued at USD 4.3 billion in 2025 and is projected to grow from USD 5.0 billion in 2026 to USD 14.3 billion by 2033, at a CAGR of 16.3% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 41.2% in 2025. The rising prevalence of liver cancer, advancement in treatment options, growing awareness and early diagnosis, rising healthcare expenditure, technological advancement, rising investment in research and development (R&D), government initiatives to increase access to care and promoting research in oncology are some the key drivers propelling the market growth.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

A liver cancer drug is a medication used to treat liver cancer by targeting specific cancer cells or pathways. These drugs include chemotherapy agents such as gemcitabine and oxaliplatin, targeted therapies such as sorafenib and lenvatinib, and immunotherapies including atezolizumab. They work by inhibiting cancer growth, inducing cell death, or enhancing the immune response against cancer cells.

According to the American Cancer Society, more than 800,000 people are diagnosed with liver cancer each year, accounting for more than 700,000 deaths each year worldwide. Factors such as alcohol consumption, hepatitis B & C infections, obesity, and fatty liver disease are expected to contribute to a growing incidence rate of liver cancer. The development of novel therapies and treatment options for liver cancer, including targeted therapies, immunotherapies, chemotherapy, and combination therapies, has fuelled the market growth. These advancements have improved survival rates and quality of life for patients. Increased awareness about the importance of early detection and diagnosis of liver cancer has led more patients to seek treatment at an early stage.

To learn more about this report, Download Free Sample Report

The increasing healthcare expenditure globally and government initiatives to improve access to healthcare services have contributed to the market growth. Technological advancements in healthcare are improving the diagnosis process. The rise of precision medicine allows for tailored treatment plans based on a patient’s needs.

Market Dynamics

The liver cancer drug market is witnessing steady growth due to the rising incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma, increasing awareness of early diagnosis, and broader access to advanced treatment options. The market is shifting from conventional chemotherapy toward targeted therapies and immunotherapies that provide improved clinical outcomes for eligible patients. Growing use of biomarker-based treatment selection and combination regimens is expanding therapeutic options for advanced liver cancer. Continued investment in clinical research is supporting the development of novel drug candidates, additional indications, and earlier-line treatment strategies. Furthermore, increasing healthcare expenditure, improving cancer care infrastructure in emerging countries, and expanding regulatory support for innovative oncology therapies are contributing to market growth. The presence of multiple approved targeted agents and immune checkpoint inhibitors, along with a strong pipeline of investigational therapies, is expected to strengthen treatment availability and support the continued growth of the liver cancer drug market during the forecast period.

Analyst Perspective

The liver cancer drug market is shifting from conventional chemotherapy toward targeted therapies and immunotherapies, supported by continued progress in molecular research, biomarker-guided treatment, and combination therapy development. The market is becoming more focused on companies with established oncology portfolios, strong clinical development programs, and experience in liver cancer treatment. Bristol-Myers Squibb Company and Bayer AG continue to maintain a strong position through their approved therapies and ongoing clinical studies in hepatocellular carcinoma. Eisai Co., Ltd. and Exelixis, Inc. are expanding the use of targeted therapies through clinical research and combination treatment strategies. Similarly, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novartis AG, and Eli Lilly and Company are strengthening their oncology portfolios by advancing new therapeutic approaches, expanding clinical programs, and supporting the development of precision medicine for liver cancer treatment.

Therapy Insights

Based on therapy, the targeted therapy segment led the market with the largest revenue share of 52.3% in 2025, owing to its precision in targeting specific molecules or pathways involved in the growth and spread of cancer cells. In addition, targeted therapy aims to minimize damage to normal cells, thus reducing side effects and improving patient outcomes. Furthermore, in the case of liver cancer, targeted therapy has been identified as having promising results in inhibiting tumor growth and improving survival rates.

The immunotherapy segment is expected to grow at the fastest CAGR of 23.5% over the forecast period. Immunotherapy has shown promising results in treating liver cancer by harnessing the immune system to target and destroy cancer cells. This approach has demonstrated significant efficacy, increasing adoption and investment in immunotherapy for liver cancer treatment.

Type Insights

Based on type, the hepatocellular carcinoma segment led the market with the largest revenue share of 38.2% in 2025. HCC Is the most common type of primary liver cancer. The high prevalence and mortality rate due to HCC is leading to research and development to find effective drugs and therapies. HCC has been challenging to treat and has limited treatment options, which leads companies to invest in new and effective drugs and therapies. Furthermore, growing awareness and early detection of liver cancer allows timely intervention and treatment, driving the demand for the drug.

The cholangio carcinoma segment is expected to grow at the fastest CAGR of 7.9% over the forecast period, primarily driven by the increasing incidence rates and rising awareness. Furthermore, cholangiocarcinoma's aggressive nature and limited treatment options necessitate more effective therapies, leading to increased research and development. Moreover, collaborations between pharmaceutical companies and healthcare organizations are propelling clinical trials and novel treatments, further boosting market expansion.

Distribution Channel Insights

Based on distribution channel, the hospital pharmacies segment led the market with the largest revenue share of 45.6% in 2025. This growth can be attributed to the increasing prevalence of cancer, and treatments & technologies available in hospital facilities are driving the hospital pharmacy market growth. Hospitals serve as primary diagnosis and treatment centers, offering access to newly approved drugs. Furthermore, this centralized care model enhances patient outcomes and supports the adoption of innovative therapies, making hospital pharmacies a key distribution channel.

To learn more about this report, Download Free Sample Report

Online pharmacies are expected to grow at a CAGR of 20.5% over the forecast period, attributed to convenience and accessibility. Their role in the liver cancer drug market is limited due to the specialized nature of these medications. Online platforms are expanding by offering services such as home delivery and telemedicine, which can improve patient compliance and access to care, though regulatory challenges remain a barrier.

Regional Insights

North America dominated the liver cancer drug market with the largest revenue share of 41.2% in 2025. It can be attributed to increasing awareness, advanced healthcare infrastructure and advanced medical technologies in the region. In addition, the strong regulatory framework ensures safe drugs, boosting patient trust. Key market players and ongoing R&D activities enhance the market. The advanced infrastructure supports the development of innovative treatments, further driving market expansion and improving patient outcomes.

To learn more about this report, Download Free Sample Report

U.S. Liver Cancer Drug Market Trends

The liver cancer drug market in the U.S. held the largest share in the North America region in 2025., driven by the increasing investment in pharmaceuticals. The regulatory framework in the U.S. ensures only safe and effective drugs reach the market which increases trust of patients and healthcare providers in the drugs. Furthermore, major players and novel treatment launches contribute to its dominance. Regulatory approvals for innovative drugs support market expansion, making the U.S. a leader in liver cancer treatments. This environment fosters continuous innovation and growth.

Asia Pacific Liver Cancer Drug Market Trends

Asia Pacific liver cancer drug market is expected to grow at the fastest CAGR of 19.6% from 2025 to 2030. This growth is due to the significantly increasing investments in liver cancer drug technologies across the region. In addition, enhanced clinical research and a large target audience create opportunities. Furthermore, countries such as China offer significant potential due to unsatisfied medical needs, making it an attractive market for pharmaceutical companies. This region's diverse healthcare systems also support market expansion.

The liver cancer drug market in China dominated the Asia Pacific market and accounted for the highest share in 2024, primarily driven by its large population and increasing demand for liver cancer treatments. Furthermore, expanding healthcare infrastructure and clinical research activities create favorable conditions for pharmaceutical investments. Moreover, innovative therapies are increasingly sought after to address the rising incidence of liver cancer. Government support for healthcare development further boosts market growth.

Europe Liver Cancer Drug Market Trends

Europe liver cancer drug marketis expected to grow significantly over the forecast period. The market is primarily driven by factors such as the growing elderly population, increasing incidence of liver cancer, advancements in treatment and diagnosis procedures, and the rise in demand for minimally invasive cancer treatment techniques. In addition, increased funding for medicinal products and demand for targeted therapies contribute to growth. Furthermore, the region's strong healthcare systems support the adoption of new treatments, enhancing patient care and outcomes.

The liver cancer drug market in Germany led the European market and held the largest revenue share in 2024, driven by increased funding for cancer research and the adoption of advanced medical technologies. In addition, demand for minimally invasive treatments and targeted therapies supports expansion. Furthermore, the country's strong healthcare system and innovative research environment make it a liver cancer drug development hub. Collaborations between academia and industry further enhance market potential.

Key Liver Cancer Drug Company Insights

Key companies in the liver cancer drug industry include Exelixis, Inc., Merck KGaA, Eisai Co., Ltd., and others. These players implement strategies such as investing in R&D, launching novel drugs, forming strategic partnerships, and expanding distribution networks to enhance their portfolios and expand their market presence. Furthermore, they also focus on regulatory compliance and improving patient access to treatments.

Exelixis operates in the oncology segment, manufacturing drugs such as CABOMETYX (cabozantinib), used for treating liver cancer. The company focuses on developing targeted therapies for various cancers, including liver cancer. Its products are designed to improve patient outcomes by targeting specific pathways involved in cancer growth.

Merck KGaA operates in the pharmaceutical segment, offering a range of oncology treatments. The company collaborates with other firms to develop innovative cancer therapies, including those for liver cancer. Its products and partnerships focus on enhancing cancer care through advanced treatments and technologies.

Key Liver Cancer Drug Companies

The following key companies have been profiled for this study on the liver cancer drug market.

• Exelixis, Inc.

• Merck KGaA

• Eisai Co., Ltd.

• Bristol-Myers Squibb Company

• Thermo Fisher Scientific Inc.

• Pfizer Inc.

• Eli Lilly and Company

• F. Hoffmann-La Roche Ltd

• Novartis AG

• Bayer AG

Recent Developments

• In January 2025, Bristol Myers Squibb received a positive CHMP opinion for Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for non-resectable or advanced hepatocellular carcinoma, a form of liver cancer. This combination, a potential live cancer drug, demonstrated improved complete survival compared to existing treatments. The approval offers new hope for patients with this challenging condition, providing an innovative approach to liver cancer treatment.

• In March 2024, Bayer AG and Thermo Fisher Scientific Inc. joined forces to enhance patient access to precision cancer medicines, including a potential live cancer drug. The collaboration focused on developing advanced next-generation sequencing companion diagnostics (CDx) to pinpoint individuals who could benefit from Bayer's expanding range of targeted cancer treatments.

Global Liver Cancer Drug Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global liver cancer drug market report based on therapy, type, distribution channel and region:

To learn more about this report, Download Free Sample Report

• Therapy Outlook (Revenue, USD Million, 2021 - 2033)

  • Targeted Therapy

  • Immunotherapy

  • Chemotherapy

  • Others

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Hepatocellular Carcinoma

  • Cholangio Carcinoma

  • Hepatoblastoma

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies 

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The liver cancer drug market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each liver cancer drug segment quantified using the revenue-capture definitions in the table below.

Estimation Model

To learn more about this report, Download Free Sample Report

The study incorporated a combination of primary and secondary research methodologies to evaluate the global liver cancer drug market. Secondary research involved the review of company annual reports, investor presentations, regulatory filings, clinical trial registries, treatment guidelines, scientific publications, cancer registries, government health databases, industry journals, and publicly available information from pharmaceutical companies, regulatory authorities, and oncology organizations. Epidemiology data, treatment guidelines, drug approvals, and pricing information were analyzed to estimate the diagnosed and treated patient population across major regions. Primary research included interviews and discussions with pharmaceutical manufacturers, oncologists, hepatologists, hospital pharmacists, researchers, business development executives, and key opinion leaders to validate disease prevalence, treatment patterns, drug adoption, pricing trends, competitive developments, and market assumptions. The findings from both research approaches were triangulated to estimate the market size, validate segment-level estimates, and ensure the accuracy of regional and global market forecasts.

Delivered Customizations

This report has been delivered with the following In-depth customizations